▶ 調査レポート

継続的腎代替療法の世界市場:モード別、製品別、療法別、エンドユーザー別

• 英文タイトル:Continuous Renal Replacement Therapy Market (Mode: Slow Continuous Ultrafiltration (SCUF), Continuous Venovenous Haemofiltration (CVVHF), Continuous Venovenous Haemodialysis (CVVHD), and Continuous Venovenous Haemodiafiltration (CVVHDF); Product: Dialysate & Replacement Fluids, Disposables, and Systems; Therapy: Renal, Non-renal, and Combination; End User: Hospitals, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• レポートコード:TPM-NV212
• 出版社/出版日:Transparency Market Research / 2019年10月
• レポート形態:英文、PDF、243ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、継続的腎代替療法の世界市場について調べ、継続的腎代替療法の世界市場規模、市場動向、市場シェア、市場環境、市場予測、モード別(低速連続限外ろ過(SCUF)、連続静脈静脈血液ろ過(CVVHF)、連続静脈静脈血液透析(CVVHD)、および連続静脈静脈血液透析(CVVHDF))分析、製品別(透析液&交換液、使い捨て、およびシステム)分析、療法別(腎、非腎、および併用)分析、エンドユーザー別(病院、診療所、その他)分析、関連企業情報などをまとめました。
・継続的腎代替療法の市場概要
・継続的腎代替療法の市場動向
・継続的腎代替療法の世界市場規模・予測
・継続的腎代替療法市場:モード別(低速連続限外ろ過(SCUF)、連続静脈静脈血液ろ過(CVVHF)、連続静脈静脈血液透析(CVVHD)、および連続静脈静脈血液透析(CVVHDF))
・継続的腎代替療法市場:製品別(透析液&交換液、使い捨て、およびシステム)
・継続的腎代替療法市場:製品別(透析液&交換液、使い捨て、およびシステム)
・継続的腎代替療法市場:エンドユーザー別(病院、診療所、その他)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Growing incidences of acute kidney injury (AKI) have catalyzed the need for improved and quality treatment therapies in the continuous renal replacement therapy (CRRT) landscape. South East Asia and South America, individually, account for ~31% each, of the hospitalized population suffering from acute kidney injury in 2018. With the help of several clinical trials, continuous venovenous haemodiafiltration (CVVHDF) and the continuous venovenous heamofiltration (CVVHF) mode of therapies have helped improve the survival rates in patients suffering from sepsis-induced acute kidney injury (SAKI).

As such, healthcare providers in hospitals are adopting continuous extracorporeal therapies to cater to the growing need for multi-organ support in critically-ill patients. The introduction of continuous renal replacement therapy has helped healthcare providers safely perform extracorporeal therapies in intensive care units (ICUs) that are less equipped with dialysis infrastructure. New advancements in continuous renal replacement therapy have also helped provide improved medical care to patients with hemodynamic tolerance concerns. Thus, manufacturers should innovate on venovenous systems and modern integrated full-volume pump monitors to help healthcare institutions carry out safe extracorporeal therapies.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Continuous Renal Replacement Therapy Market

4. Market Overview

4.1. Introduction

4.1.1. Market Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Continuous Renal Replacement Therapy Market Analysis Forecast, 2017–2027

4.4.1. Market Revenue Projection (US$ Mn)

5. Market Outlook

5.1. Incidence of Acute Kidney Injury Across the Globe

5.2. Rise in Prevalence of Diabetes and Hypertension

5.3. Reimbursement Scenario by Region/globally

5.4. Regulatory Scenario by Region/globally

5.5. Recent Technological Developments in Continuous Renal Replacement Therapy

5.6. Development of CRRT System for Paediatric Patients

5.7. Key Mergers & Acquisitions

6. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Mode

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Continuous Renal Replacement Therapy Market Value (US$) Forecast, by Mode, 2017–2027

6.3.1. Slow Continuous Ultrafiltration (SCUF)

6.3.2. Continuous VenoVenous Haemofiltration (CVVHF)

6.3.3. Continuous VenoVenous Haemodialysis (CVVHD)

6.3.4. Continuous VenoVenous Haemodiafiltration (CVVHDF)

6.4. Continuous Renal Replacement Therapy Market Attractiveness, by Mode

7. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Product

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

7.3.1. Dialysate & Replacement Fluids

7.3.2. Disposables

7.3.2.1. Bloodline Sets

7.3.2.2. Hemofilters

7.3.2.3. Other Disposables

7.3.3. Systems

7.4. Continuous Renal Replacement Therapy Market Attractiveness, by Product

8. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Therapy

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

8.3.1. Renal

8.3.2. Non-renal

8.3.3. Combination

8.4. Continuous Renal Replacement Therapy Market Attractiveness, by Therapy

9. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by End-user

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

9.3.1. Hospitals

9.3.2. Clinics

9.3.3. Others

9.4. Continuous Renal Replacement Therapy Market Attractiveness, by End-user

10. Global Continuous Renal Replacement Therapy Market Analysis Forecast, by Region

10.1. Key Findings

10.2. Continuous Renal Replacement Therapy Market Value Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Continuous Renal Replacement Therapy Market Attractiveness, by Country/Region

11. North America Continuous Renal Replacement Therapy Market Analysis

11.1. Introduction

11.1.1. Key Findings

11.2. North America Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027

11.2.1. Slow Continuous Ultrafiltration (SCUF)

11.2.2. Continuous Venovenous Haemofiltration (CVVHF)

11.2.3. Continuous Venovenous Haemodialysis (CVVHD)

11.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)

11.3. North America Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

11.3.1. Dialysate & Replacement Fluids

11.3.2. Disposables

11.3.2.1. Bloodline Sets

11.3.2.2. Hemofilters

11.3.2.3. Other Disposables

11.3.3. Systems

11.4. North America Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

11.4.1. Renal

11.4.2. Non-renal

11.4.3. Combination

11.5. North America Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

11.5.1. Hospitals

11.5.2. Clinics

11.5.3. Others

11.6. North America Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027

11.6.1. U.S.

11.6.2. Canada

11.7. North America Continuous Renal Replacement Therapy Market Attractiveness Analysis

11.7.1. By Mode

11.7.2. By Product

11.7.3. By Therapy

11.7.4. By End-user

11.7.5. By Country

12. Europe Continuous Renal Replacement Therapy Market Analysis

12.1. Introduction

12.1.1. Key Findings

12.2. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027

12.2.1. Slow Continuous Ultrafiltration (SCUF)

12.2.2. Continuous Venovenous Haemofiltration (CVVHF)

12.2.3. Continuous Venovenous Haemodialysis (CVVHD)

12.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)

12.3. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

12.3.1. Dialysate & Replacement Fluids

12.3.2. Disposables

12.3.2.1. Bloodline Sets

12.3.2.2. Hemofilters

12.3.2.3. Other Disposables

12.3.3. Systems

12.4. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

12.4.1. Renal

12.4.2. Non-renal

12.4.3. Combination

12.5. Europe Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

12.5.1. Hospitals

12.5.2. Clinics

12.5.3. Others

12.6. Europe Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Rest of Europe

12.7. Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis

12.7.1. By Mode

12.7.2. By Product

12.7.3. By Therapy

12.7.4. By End-user

12.7.5. By Country

13. Asia-Pacific Continuous Renal Replacement Therapy Market Analysis

13.1. Introduction

13.1.1. Key Findings

13.2. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027

13.2.1. Slow Continuous Ultrafiltration (SCUF)

13.2.2. Continuous Venovenous Haemofiltration (CVVHF)

13.2.3. Continuous Venovenous Haemodialysis (CVVHD)

13.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)

13.3. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

13.3.1. Dialysate & Replacement Fluids

13.3.2. Disposables

13.3.2.1. Bloodline Sets

13.3.2.2. Hemofilters

13.3.2.3. Other Disposables

13.3.3. Systems

13.4. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

13.4.1. Renal

13.4.2. Non-renal

13.4.3. Combination

13.5. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

13.5.1. Hospitals

13.5.2. Clinics

13.5.3. Others

13.6. Asia-Pacific Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027

13.6.1. China

13.6.2. Japan

13.6.3. India

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Asia-Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis

13.7.1. By Mode

13.7.2. By Product

13.7.3. By Therapy

13.7.4. By End-user

13.7.5. By Country

14. Latin America Continuous Renal Replacement Therapy Market Analysis

14.1. Introduction

14.1.1. Key Findings

14.2. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027

14.2.1. Slow Continuous Ultrafiltration (SCUF)

14.2.2. Continuous Venovenous Haemofiltration (CVVHF)

14.2.3. Continuous Venovenous Haemodialysis (CVVHD)

14.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)

14.3. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

14.3.1. Dialysate & Replacement Fluids

14.3.2. Disposables

14.3.2.1. Bloodline Sets

14.3.2.2. Hemofilters

14.3.2.3. Other Disposables

14.3.3. Systems

14.4. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

14.4.1. Renal

14.4.2. Non-renal

14.4.3. Combination

14.5. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

14.5.1. Hospitals

14.5.2. Clinics

14.5.3. Others

14.6. Latin America Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis

14.7.1. By Mode

14.7.2. By Product

14.7.3. By Therapy

14.7.4. By End-user

14.7.5. By Country

15. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis

15.1. Introduction

15.1.1. Key Findings

15.2. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Mode, 2017–2027

15.2.1. Slow Continuous Ultrafiltration (SCUF)

15.2.2. Continuous Venovenous Haemofiltration (CVVHF)

15.2.3. Continuous Venovenous Haemodialysis (CVVHD)

15.2.4. Continuous Venovenous Haemodiafiltration (CVVHDF)

15.3. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Product, 2017–2027

15.3.1. Dialysate & Replacement Fluids

15.3.2. Disposables

15.3.2.1. Bloodline Sets

15.3.2.2. Hemofilters

15.3.2.3. Other Disposables

15.3.3. Systems

15.4. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Therapy , 2017–2027

15.4.1. Renal

15.4.2. Non-renal

15.4.3. Combination

15.5. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by End-user , 2017–2027

15.5.1. Hospitals

15.5.2. Clinics

15.5.3. Others

15.6. Middle East & Africa Continuous Renal Replacement Therapy Market Value Forecast, by Country, 2017–2027

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis

15.7.1. By Mode

15.7.2. By Product

15.7.3. By Therapy

15.7.4. By End-user

15.7.5. By Country

16. Competition Landscape

16.1. Market Player – Competition Matrix (By Tier and Size of companies)

16.2. Market Position By Company (2018)

16.3. Company Profiles

16.3.1. Baxter International, Inc

16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.1.2. Financial Overview

16.3.1.3. Product Portfolio

16.3.1.4. Strategic Overview

16.3.1.5. SWOT Analysis

16.3.2. Nipro Corporation

16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.2.2. Financial Overview

16.3.2.3. Product Portfolio

16.3.2.4. Strategic Overview

16.3.2.5. SWOT Analysis

16.3.3. Fresenius Medical Care AG & Co. KGaA

16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.3.2. Financial Overview

16.3.3.3. Product Portfolio

16.3.3.4. Strategic Overview

16.3.3.5. SWOT Analysis

16.3.4. Asahi Kasei Corporation

16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.4.2. Financial Overview

16.3.4.3. Product Portfolio

16.3.4.4. Strategic Overview

16.3.4.5. SWOT Analysis

16.3.5. B. Braun Melsungen AG

16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.5.2. Financial Overview

16.3.5.3. Product Portfolio

16.3.5.4. Strategic Overview

16.3.5.5. SWOT Analysis

16.3.6. NIKKISO CO., LTD

16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.6.2. Financial Overview

16.3.6.3. Product Portfolio

16.3.6.4. Strategic Overview

16.3.6.5. SWOT Analysis

16.3.7. Medica SPA

16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.7.2. Product Portfolio

16.3.7.3. Strategic Overview

16.3.7.4. SWOT Analysis

16.3.8. INFOMED SA

16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.8.2. Product Portfolio

16.3.8.3. Strategic Overview

16.3.8.4. SWOT Analysis

16.3.9. Medtronic (Bellco Società unipersonale a r.l.)

16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.9.2. Financial Overview

16.3.9.3. Product Portfolio

16.3.9.4. Strategic Overview

16.3.9.5. SWOT Analysis

16.3.10. Toray Medical Company Limited (Toray Industries, Inc.)

16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.10.2. Product Portfolio

16.3.10.3. Strategic Overview

16.3.10.4. SWOT Analysis




• 英文レポート名:Continuous Renal Replacement Therapy Market (Mode: Slow Continuous Ultrafiltration (SCUF), Continuous Venovenous Haemofiltration (CVVHF), Continuous Venovenous Haemodialysis (CVVHD), and Continuous Venovenous Haemodiafiltration (CVVHDF); Product: Dialysate & Replacement Fluids, Disposables, and Systems; Therapy: Renal, Non-renal, and Combination; End User: Hospitals, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
• 日本語訳:継続的腎代替療法の世界市場:モード別、製品別、療法別、エンドユーザー別
• レポートコード:TPM-NV212お問い合わせ(見積依頼・ご注文・質問)